Table 6.
Conversion and reversion rates at 6, 12 and 18 months stratified by quantitative IFN-gamma values at study enrollment (using conversion definition A: ⩾0.35 IU/ml).
| QFT at study enrollment: TB Ag- Nil (IU/ml) | Participants with result, n (%) | Conversions at QFT 2 | Conversions at QFT 3 | Conversions at QFT 4 | Reversions at QFT3 | Reversions at QFT 4 |
|---|---|---|---|---|---|---|
| <0.01 | 68 (31%) | 10/68 (15%) | 5/58 (9%) | 11/61 (18%) | 8/10 (80%) | 4/7 (57%) |
| 0.01–0.19 | 75 (34%) | 5/75 (7%) | 13/70 (19%) | 14/61 (23%) | 4/5 (80%) | 8/14(57%) |
| 0.2–0.34 | 16 (7%) | 3/16 (19%) | 2/13 (15%) | 3/13 (23%) | 2/3 (67%) | 2/3 (67%) |
| Reversions at QFT 2 | ||||||
| 0.35–0.49 | 5 (2%) | 2/5 (40%) | 1/2 (50%) | 1/2 (50%) | 1/3 (33%) | 1/3 (33%) |
| 0.5–0.69 | 4 (2%) | 4/4 (100%) | 3/4 (75%) | 1/1 (100%) | – | 1/3 (33%) |
| 0.7–0.99 | 6 (3%) | 3/6 (50%) | 1/3 (33%) | 1/2 (50%) | 0/3 (0%) | 2/4 (50%) |
| 1–2.99 | 12 (5%) | 5/12 (42%) | 4/5 (80%) | 1/1 (100%) | 0/7 (0%) | 4/11 (36%) |
| 3.00+ | 34 (15%) | 2/34 (6%) | 1/2 (50%) | 1/2 (50%) | 1/32 (3%) | 1/32 (3%) |